^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S-531011

    i
    Associations

    News

    Trials
    Company:
    Shionogi
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=274, Recruiting, Shionogi | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • S-531011
    over3years
    S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs (SITC 2021)
    On the other hand, S-531011 didn’t reduce Tregs in human PBMC. Conclusions S-531011 is a promising drug which has a strong antitumor effect by depleting tumor-infiltrating CCR8+ Tregs, as a not only monotherapy but also combination therapy with other immune checkpoint inhibitors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression
    |
    S-531011